D05 Stock Overview
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Deciphera Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.80 |
| 52 Week High | US$15.94 |
| 52 Week Low | US$9.51 |
| Beta | 0.39 |
| 1 Month Change | 0.91% |
| 3 Month Change | 9.52% |
| 1 Year Change | 4.66% |
| 3 Year Change | -63.30% |
| 5 Year Change | -35.48% |
| Change since IPO | -18.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| D05 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -4.8% | -4.9% | -1.5% |
| 1Y | 4.7% | -19.9% | 0.9% |
Return vs Industry: D05 exceeded the German Biotechs industry which returned -19.4% over the past year.
Return vs Market: D05 exceeded the German Market which returned -0.4% over the past year.
Price Volatility
| D05 volatility | |
|---|---|
| D05 Average Weekly Movement | 6.6% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: D05 has not had significant price volatility in the past 3 months.
Volatility Over Time: D05's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 355 | Steve Hoerter | www.deciphera.com |
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage.
Deciphera Pharmaceuticals, Inc. Fundamentals Summary
| D05 fundamental statistics | |
|---|---|
| Market cap | €1.14b |
| Earnings (TTM) | -€183.15m |
| Revenue (TTM) | €153.47m |
7.2x
P/S Ratio-6.0x
P/E RatioIs D05 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| D05 income statement (TTM) | |
|---|---|
| Revenue | US$163.36m |
| Cost of Revenue | US$237.86m |
| Gross Profit | -US$74.50m |
| Other Expenses | US$120.44m |
| Earnings | -US$194.94m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.37 |
| Gross Margin | -45.61% |
| Net Profit Margin | -119.34% |
| Debt/Equity Ratio | 0% |
How did D05 perform over the long term?
See historical performance and comparison